褐色細胞腫の世界市場レポート 2024年

褐色細胞腫の市場規模は近年着実に成長しています。2023年の28億9,000万米ドルから2024年には30億3,000万米ドルに、CAGR4.9％で拡大します。実績期間の成長は、ヘルスケア支出の増加、診断と認知度の向上、遺伝子研究、政府の取り組みに起因します。

腫瘍の罹患率の上昇は、当面の褐色細胞腫市場の成長を促進します。異常な細胞増殖である腫瘍には、良性（非がん性）と悪性（がん性）があります。腫瘍やがんの症例が増加していることから、褐色細胞腫を効果的に管理するための医療意識の向上、正確な診断、オーダーメイドの治療戦略の必要性が強調されています。例えば、2023年1月現在、米国がん協会は、がんの症例数が195万8310件に増加し、2021年の189万8160件から3.16％増加したと報告しています。その結果、腫瘍の急増が今後数年間の褐色細胞腫市場の成長を促進すると予想されます。

2023年の褐色細胞腫市場で最大の地域は北米でした。アジア太平洋は予測期間中に最も急成長する地域となる見込みです。褐色細胞腫レポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の褐色細胞腫市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 副腎褐色細胞腫
• 副腎外褐色細胞腫
• 世界の褐色細胞腫市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 薬剤
• 手術
• 放射性核種治療
• その他の治療
• 世界の褐色細胞腫市場、診断別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 臨床検査
• 画像検査
• 遺伝子検査
• 世界の褐色細胞腫市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院
• クリニック
• 検査および学術機関
• その他

第7章 地域および国の分析

• 世界の褐色細胞腫市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
• 世界の褐色細胞腫市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 褐色細胞腫市場の競合情勢
• 褐色細胞腫市場の企業プロファイル
  • Pfizer Inc.
  • AbbVie Inc.
  • Novartis AG
  • Sanofi SA
  • Bristol-Myers Squibb Company

第31章 その他の主要および革新的な企業

• AstraZeneca Plc
• Abbott Laboratories
• Takeda Pharmaceutical Company Limited
• Merck KGaA
• Baxter International Inc.
• Teva Pharmaceutical Company Limited
• Mylan N.V.
• Bausch Health Companies Inc.
• Daiichi Sankyo Company Limited
• Eisai Co. Ltd.
• Apotex Inc.
• Sun Pharmaceutical Industries Ltd.
• Hikma Pharmaceuticals PLC
• Endo International plc
• Exelixis Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

“Pheochromocytoma Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pheochromocytoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pheochromocytoma? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The pheochromocytoma market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type: Adrenal Pheochromocytoma; Extra-Adrenal Pheochromocytoma
• 2) By Treatment: Medication; Surgery; Radionuclide Treatment; Other Treatments
• 3) By Diagnosis: Laboratory Tests; Imaging Tests; Genetic Testing
• 4) By End Users: Hospitals; Clinics; Research And Academic Institutes; Other End Users
• Companies Mentioned: Pfizer Inc.; AbbVie Inc.; Novartis AG; Sanofi S.A.; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Pheochromocytoma is a rare tumor that forms in the center of one or both adrenal glands. These tumors arise from the adrenal medulla cells, which are responsible for producing hormones such as adrenaline (epinephrine) and noradrenaline (norepinephrine). Pheochromocytomas can lead to excessive secretion of these hormones, causing symptoms like high blood pressure, rapid heartbeat, anxiety and related effects.

The main types of pheochromocytomas are adrenal pheochromocytomas and extra-adrenal pheochromocytomas. Adrenal pheochromocytoma refers to a specific type of pheochromocytoma that originates in the adrenal glands, which are located on top of the kidneys and can lead to the excessive production of hormones like adrenaline and noradrenaline, causing symptoms such as high blood pressure and a rapid heart rate. The treatment for pheochromocytoma includes medication, surgery, radionuclide treatment and others, as well as laboratory tests, imaging tests and genetic testing, which are integrated for the diagnosis of pheochromocytoma and provided by end users such as hospitals, clinics, research and academic institutes and others.

The pheochromocytoma market research report is one of a series of new reports from The Business Research Company that provides pheochromocytoma market statistics, including pheochromocytoma industry global market size, regional shares, competitors with a pheochromocytoma market share, detailed pheochromocytoma market segments, market trends and opportunities and any further data you may need to thrive in the pheochromocytoma industry. This pheochromocytoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pheochromocytoma market size has grown steadily in recent years. It will grow from $2.89 billion in 2023 to $3.03 billion in 2024 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to rise in healthcare expenditure, increased diagnosis and awareness, genetic research, government initiatives.

The pheochromocytoma market size is expected to see steady growth in the next few years. It will grow to $3.56 billion in 2028 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to demand for combination therapies, investment in pheochromocytoma research and development, demand for minimally invasive pheochromocytoma treatments, high rare disease research initiatives. Major trends in the forecast period include increase in the number of drugs in clinical trials, advancements in diagnosis and treatment options, growing expertise in gene therapy, advancements in medical imaging.

The rising incidence of tumors is set to drive the growth of the pheochromocytoma market in the foreseeable future. Tumors, which are abnormal cell growths, can be either benign (non-cancerous) or malignant (cancerous). The escalating cases of tumors and cancers underscore the necessity for heightened medical awareness, precise diagnostics, and tailored treatment strategies to effectively manage pheochromocytoma. For instance, as of January 2023, the American Cancer Society reported an increase in cancer cases to 1,958,310, marking a 3.16% growth from 1,898,160 cases in 2021. Consequently, the surging incidence of tumors is expected to propel the pheochromocytoma market's growth in the coming years.

The future growth of the pheochromocytoma market is expected to be propelled by the increasing incidence of neuroendocrine diseases. Neuroendocrine diseases encompass a group of medical conditions affecting the complex neuroendocrine system, responsible for hormone production and regulation. The growing occurrence of neuroendocrine diseases, including pheochromocytomas, may lead to a heightened demand for specialized diagnostics, treatments, surgical procedures, pharmaceuticals, and patient support services tailored to this particular condition. For instance, data from the American Society of Clinical Oncology (ASCO) in March 2023 suggests that neuroendocrine diseases, such as pheochromocytoma, are estimated to have an annual incidence ranging from 2 to 8 cases per 1 million individuals, with approximately 15% of these cases being cancerous. Moreover, the 5-year relative survival rate for recurrent or metastatic pheochromocytomas is projected to be between 34% and 60%. Therefore, the increasing prevalence of neuroendocrine diseases is poised to be a driving factor for the pheochromocytoma market's growth in the future.

Insufficient awareness about the disease acts as a hindrance to the growth of the pheochromocytoma market during the forecast period. This lack of awareness creates challenges for individuals affected by pheochromocytoma, potentially resulting in delays in diagnosis and limited opportunities for regular screening. For example, as reported by the National Library of Medicine, India has experienced delayed pheochromocytoma diagnoses due to factors like insufficient knowledge, limited diagnostic facilities, and the generic nature of symptoms associated with the condition. As a result, the limited awareness of the disease is impeding the expansion of the pheochromocytoma market.

Prominent companies in the pheochromocytoma market are actively conducting clinical trials to evaluate novel treatment approaches, therapies, and medications for pheochromocytoma. This initiative aims to develop more effective and targeted treatments, ultimately enhancing patient outcomes. For example, in August 2022, Switzerland-based pharmaceutical company Novartis AG initiated Phase 2 of a multicenter open-label study to assess the safety and dosimetry of Lutathera in adolescents aged 12 to under 18 with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and pheochromocytoma and paragangliomas (PPGL). The study adopts a multicenter, open-label, single-arm approach, including an exploratory PPGL cohort designed to encompass as many adolescents with PPGL as possible.

In May 2021, France-based nuclear medicine company Curium Pharma acquired IASON GmbH for an undisclosed amount. This strategic acquisition extends Curium's presence in Europe and enhances its comprehensive range of critical diagnostic solutions aimed at saving lives. IASON GmbH, headquartered in Austria, specializes in radiopharmaceuticals, particularly positron emission tomography (PET) tracers for diagnosing pheochromocytoma.

Major players in the pheochromocytoma market are Pfizer Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Merck KGaA, Baxter International Inc., Teva Pharmaceutical Company Limited, Mylan N.V., Bausch Health Companies Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Apotex Inc., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Endo International PLC, Exelixis Inc., Lupin Limited, Lantheus Holdings Inc., Curium Pharma, ANI Pharmaceuticals Inc., Jubilant Cadista Pharmaceuticals Inc., WellSpring Pharmaceutical Corporation, HRA Pharma SE.

North America was the largest region in the pheochromocytoma market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pheochromocytoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pheochromocytoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pheochromocytoma market consists of revenues earned by entities by providing ablation therapy, embolization therapy and targeted therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The pheochromocytoma market also includes sales of prazosin, terazosin and doxazosin, which are used in providing pheochromocytoma treatment. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Pheochromocytoma Market Characteristics

3. Pheochromocytoma Market Trends And Strategies

4. Pheochromocytoma Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Pheochromocytoma Market Size and Growth

• 5.1. Global Pheochromocytoma Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Pheochromocytoma Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Pheochromocytoma Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Pheochromocytoma Market Segmentation

• 6.1. Global Pheochromocytoma Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Adrenal Pheochromocytoma
• Extra-Adrenal Pheochromocytoma
• 6.2. Global Pheochromocytoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Medication
• Surgery
• Radionuclide Treatment
• Other Treatments
• 6.3. Global Pheochromocytoma Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Laboratory Tests
• Imaging Tests
• Genetic Testing
• 6.4. Global Pheochromocytoma Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Clinics
• Research And Academic Institutes
• Other End Users

7. Pheochromocytoma Market Regional And Country Analysis

• 7.1. Global Pheochromocytoma Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Pheochromocytoma Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Pheochromocytoma Market

• 8.1. Asia-Pacific Pheochromocytoma Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Pheochromocytoma Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Pheochromocytoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Pheochromocytoma Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Pheochromocytoma Market

• 9.1. China Pheochromocytoma Market Overview
• 9.2. China Pheochromocytoma Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Pheochromocytoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Pheochromocytoma Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Pheochromocytoma Market

• 10.1. India Pheochromocytoma Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Pheochromocytoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Pheochromocytoma Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Pheochromocytoma Market

• 11.1. Japan Pheochromocytoma Market Overview
• 11.2. Japan Pheochromocytoma Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Pheochromocytoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Pheochromocytoma Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Pheochromocytoma Market

• 12.1. Australia Pheochromocytoma Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Pheochromocytoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Pheochromocytoma Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Pheochromocytoma Market

• 13.1. Indonesia Pheochromocytoma Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Pheochromocytoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Pheochromocytoma Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Pheochromocytoma Market

• 14.1. South Korea Pheochromocytoma Market Overview
• 14.2. South Korea Pheochromocytoma Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Pheochromocytoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Pheochromocytoma Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Pheochromocytoma Market

• 15.1. Western Europe Pheochromocytoma Market Overview
• 15.2. Western Europe Pheochromocytoma Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Pheochromocytoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Pheochromocytoma Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Pheochromocytoma Market

• 16.1. UK Pheochromocytoma Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Pheochromocytoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Pheochromocytoma Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Pheochromocytoma Market

• 17.1. Germany Pheochromocytoma Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Pheochromocytoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Pheochromocytoma Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Pheochromocytoma Market

• 18.1. France Pheochromocytoma Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Pheochromocytoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Pheochromocytoma Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Pheochromocytoma Market

• 19.1. Italy Pheochromocytoma Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Pheochromocytoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Pheochromocytoma Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Pheochromocytoma Market

• 20.1. Spain Pheochromocytoma Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Pheochromocytoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Pheochromocytoma Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Pheochromocytoma Market

• 21.1. Eastern Europe Pheochromocytoma Market Overview
• 21.2. Eastern Europe Pheochromocytoma Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Pheochromocytoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Pheochromocytoma Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Pheochromocytoma Market

• 22.1. Russia Pheochromocytoma Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Pheochromocytoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Pheochromocytoma Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Pheochromocytoma Market

• 23.1. North America Pheochromocytoma Market Overview
• 23.2. North America Pheochromocytoma Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Pheochromocytoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Pheochromocytoma Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Pheochromocytoma Market

• 24.1. USA Pheochromocytoma Market Overview
• 24.2. USA Pheochromocytoma Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Pheochromocytoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Pheochromocytoma Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Pheochromocytoma Market

• 25.1. Canada Pheochromocytoma Market Overview
• 25.2. Canada Pheochromocytoma Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Pheochromocytoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Pheochromocytoma Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Pheochromocytoma Market

• 26.1. South America Pheochromocytoma Market Overview
• 26.2. South America Pheochromocytoma Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Pheochromocytoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Pheochromocytoma Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Pheochromocytoma Market

• 27.1. Brazil Pheochromocytoma Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Pheochromocytoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Pheochromocytoma Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Pheochromocytoma Market

• 28.1. Middle East Pheochromocytoma Market Overview
• 28.2. Middle East Pheochromocytoma Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Pheochromocytoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Pheochromocytoma Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Pheochromocytoma Market

• 29.1. Africa Pheochromocytoma Market Overview
• 29.2. Africa Pheochromocytoma Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Pheochromocytoma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Pheochromocytoma Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Pheochromocytoma Market Competitive Landscape And Company Profiles

• 30.1. Pheochromocytoma Market Competitive Landscape
• 30.2. Pheochromocytoma Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. AbbVie Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Novartis AG
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Sanofi S.A.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Bristol-Myers Squibb Company
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Pheochromocytoma Market Other Major And Innovative Companies

• 31.1. AstraZeneca Plc
• 31.2. Abbott Laboratories
• 31.3. Takeda Pharmaceutical Company Limited
• 31.4. Merck KGaA
• 31.5. Baxter International Inc.
• 31.6. Teva Pharmaceutical Company Limited
• 31.7. Mylan N.V.
• 31.8. Bausch Health Companies Inc.
• 31.9. Daiichi Sankyo Company Limited
• 31.10. Eisai Co. Ltd.
• 31.11. Apotex Inc.
• 31.12. Sun Pharmaceutical Industries Ltd.
• 31.13. Hikma Pharmaceuticals PLC
• 31.14. Endo International plc
• 31.15. Exelixis Inc.

32. Global Pheochromocytoma Market Competitive Benchmarking

33. Global Pheochromocytoma Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Pheochromocytoma Market

35. Pheochromocytoma Market Future Outlook and Potential Analysis

• 35.1 Pheochromocytoma Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Pheochromocytoma Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Pheochromocytoma Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer